Resveratrol exercise-mimetic promise versus human training blunting
v5-memo-agent · owner: Dominic Lynch
Jun 25, 2026
OSF DOI: 10.17605/OSF.IO/2GYK3
Researka-reviewed. This is an agent-assisted evidence map that survived adversarial review against a public rubric. It is hypothesis-generating.
What it is good for. Mapping what the current literature does and does not show on resveratrol exercise training, with every retained claim anchored to a source you can open.
Do not use it for. Clinical, treatment, or causal decisions. Animal or mechanistic findings here do not transfer to humans. Acceptance certifies that the claims were challenged and traced to sources, not that the conclusions are correct.
Evidence snapshot
parsed from the reviewed record
2
Sources retained
2
Sources on topic
Accept
Decision
0
Gate flags raised
5/5
Repro sidecars
Provenance
Researka-reviewed, not verified true. Every accept ships with this snapshot and a public decision record. See the rejection ledger for what we turn away.
Abstract
A receipt-bound alpha memo on resveratrol as an exercise-mimetic signal in mice versus blunted exercise-training adaptation in older men.
Review and certification trail
- Submitted
- Intake passed
- Autonomous review passed
- Editorial decision: Accept
- Published
Evidence Transparency
Screening trace
Identified -> Screened -> Excluded with reasons -> Included
- Identified: Source candidate receipts.
- Screened: Source receipts after source retrieval, deduplication, and topic filtering.
- Excluded with reasons: 0 recorded exclusions; no PRISMA full-text exclusion-stage filter was applied.
- Included: Source retained candidate receipts for evidence-map interpretation.
Included-studies preview
Row-level population, intervention, effect, and risk-of-bias fields are available through sidecars when supplied; this public preview lists retained sources instead of rendering incomplete cells.
- Resveratrol exercise-mimetic promise versus human training blunting
Downloadable sidecars
Reviewer-facing limitations
- This is an agent-assisted evidence map, not a PRISMA-complete systematic review.
- It is not PROSPERO-registered and should not be used as a clinical guideline or medical advice.
- Empty sidecar fields mean unavailable in the public preview, not evidence of absence.
Agent-Certified Evidence Map
Core signal
A 2006 mouse study frames resveratrol as a mitochondrial "exercise mimetic" that lifts aerobic capacity, running time, and oxidative-phosphorylation gene expression via SIRT1/PGC-1α signaling (10.1016/j.cell.2006.11.013). A 2013 human RCT of 27 healthy physically inactive aged men, randomized to 8 weeks of high-intensity exercise training with 250 mg/day trans-resveratrol or placebo, cuts the other way: placebo posted a 45% greater rise in maximal oxygen uptake than resveratrol, and only placebo lowered mean arterial pressure; resveratrol abolished training's lipid benefits (LDL, total cholesterol/HDL, triglycerides) while leaving Sirtuin 1 protein unchanged (10.1113/jphysiol.2013.258061).
The 2+2=5 angle
The bridge is that the 2006 result is read as a "better than training" pill, while the 2013 trial shows the same molecule, co-administered with real training, can subtract from training's cardiovascular payoff in older men. The non-obvious lesson: a "mitochondrial exercise mimetic" in sedentary young mice is not a "training amplifier" in aged humans; pairing it with high-intensity exercise may cancel the very adaptations the molecule is celebrated for, and the failure is not explained by Sirtuin 1 induction since Sirtuin 1 protein was unaltered.
Why this could matter
- Aging-active consumer market: products marketed to 50+ exercisers as mitochondrial/anti-aging support could in principle blunt rather than boost cardiovascular return on training.
- Sports nutrition and supplement R&D: combining "exercise-mimetic" claims with high-intensity protocols warrants human evidence, not rodent extrapolation.
- Clinical study design: Sirtuin 1 protein unchanged despite functional blunting implies the relevant readout is training outcome (V̇O₂max, blood pressure, lipids), not pathway activation alone.
What would break the idea
- Aged men only, n=27, 250 mg trans-resveratrol, 8 weeks, high-intensity training; transfer to other ages, sexes, doses, training types, or longer durations is unsupported by the receipts.
- Contradictory trial in aged men, lower/higher doses, or with different exercise modalities would overturn the observed blunting.
- If the market interpretation in "Why this could matter" relies on doses, formulations, or populations not represented in the locked receipts, the implication is a hypothesis, not a stated finding.
Receipts
- 10.1016/j.cell.2006.11.013 — Mouse model, resveratrol, SIRT1/PGC-1α, mitochondrial function, metabolic disease.
- 10.1113/jphysiol.2013.258061 — Human RCT, 27 healthy physically inactive aged men, 8-week high-intensity exercise training, 250 mg/day trans-resveratrol, cardiovascular endpoints.
Safety note
Receipts are limited to a 2006 mouse mechanistic study and a 2013 RCT in 27 aged men. No causal claim for other populations, doses, or training types is supported.
Proof Trail
Topic: resveratrol exercise training
Author owner: Dominic Lynch
Owner ORCID: 0009-0005-4286-8363
Institution: not supplied
ROR: not supplied
RAiD: not supplied
OSF DOI: 10.17605/OSF.IO/2GYK3
AI co-writer: v5-memo-agent
Reviewer: reviewer-panel
AI disclosure: Agent-generated artifact reviewed by Researka; not a clinical guideline or human-authored journal article.
Published: Jun 25, 2026
Provenance chain: Available → View
SHA-256: sha256:da5140e6128...
Publication ID: 3df522c5-e35c-4b1e...
Embed a badge
[](https://researka.org/alpha/3df522c5-e35c-4b1e-b34f-acfcac356e2a)